Skip to main content

EyeSol® Technology

Unlocks the untapped potential of topical ocular therapies

EyeSol® is a non-aqueous, preservative-free technology platform made of semifluorinated alkanes (SFAs), facilitating drug delivery to the biological targets driving ocular diseases.

Topical eye drops are the therapeutic pillar for many ocular diseases, but traditional water-based formulations have significant limitations that may influence efficacy and safety. EyeSol® is the worldwide first and only water-free technology for ophthalmic products. It enables solubilization of lipophilic molecules, substantially increases the ocular residence time from minutes to hours, thereby enabling high tissue penetration due to higher bioavailability of active pharmaceutical ingredients (API). EyeSol® formulations are stable at room temperature and demonstrate excellent tolerability and safety, while minimizing systemic exposure through a small drop size of less 12 µl optimized for the eye’s natural capacity.

Limitations of traditional water or oil-based formulations

Water-based ophthalmic drops typically deliver 30–50 µL, exceeding the eye’s reservoir capacity and leading to spillover. Their limited spreading, due to tear film and lipid layer surface tension, combined with reflex blinking and tear secretion, reduces ocular residence time. As a result, traditional topical formulations achieve low bioavailability of approximately 1–10%.

Another limitation of aqueous formulations is that many new chemical entities are lipophilic or poorly water-soluble. This requires the use of excipients or surfactants, which can cause side effects such as blurred vision. Additionally, preservatives required for multi-dose formulations may further impact tolerability and ocular surface health.

Novaliq’s innovative EyeSol® technology platform facilitates drug delivery to the target tissues

A novel category of topical ophthalmic therapies has been established which unlocks new possibilities for treating, relieving, and preventing a wide range of eye conditions.
  • EyeSol® formulations are water-free, non-preserved, and designed for micro-dosing, supporting both efficacy and ocular surface tolerability.
  • The platform is particularly suited for lipophilic and poorly water-soluble compounds, expanding the scope of drug development in ophthalmology.
  • EyeSol® substances are highly biocompatible and do not accumulate in human tissues.
  • We are best known for our dry eye disease category-defining products Miebo™ (Bausch + Lomb), Vevye™ (Harrow), Vevizye™ (Thea Pharma) and Heng Qin™ and Heng Yi™ (Hengrui Pharma).
  • The EyeSol® platform is proprietary to Novaliq and protected by a strong intellectual property portfolio of more than 250 granted patents.

Building on our clinical success, we have renewed our ambition and broaden our target disease focus from the anterior segment of the eye to the posterior segment.

Novaliq pursues these new opportunities where evidence-based science meets significant unmet clinical need.

Our R&D pipeline reflects our ambition to prevent vision loss for people around the world.

Safety of EyeSol® Products

EyeSol® products use highly pure raw materials sourced from qualified manufacturers. Their safety, efficacy, and tolerability have been extensively demonstrated in close collaboration with regulatory authorities.

Novaliq’s semifluorinated alkanes (SFAs) have undergone comprehensive preclinical, clinical, and ecotoxicological evaluation. SFAs are not metabolized in the human body and are physically, chemically, and physiologically inert, with excellent biocompatibility and a strong safety profile. There is further no evidence or indication for any transformation or degradation of SFAs under environmental conditions that may lead to critical substances.

EyeSol® therapies for dry eye disease are approved and commercially available in the European Union and other European countries, the United States, Australia, New Zealand, and China.

For more information on our products please contact us: info@novaliq.com